NKT cells expressing functional TCRs have advantages over engineered T cells. TCR⁺ NKT cells downregulate their invariant TCR, avoiding further engineering for optimal TCR expression and preventing TCR-chain mispairing, and show antitumor efficacy in preclinical models.